Tempest Therapeutics, Inc. 8-K

What Happened

• Tempest Therapeutics, Inc. (TPST) announced its financial results for the quarter ended March 31, 2026 by issuing a press release on May 14, 2026. The company filed an 8-K under Item 2.02 (Results of Operations and Financial Condition) to furnish that press release. The filing was signed by CEO Matthew Angel.

Key Details

• Date of filing/press release: May 14, 2026.
• Reporting period: Quarter ended March 31, 2026.
• Press release attached as Exhibit 99.1 and furnished with the 8‑K.
• Cover page interactive XBRL included (Exhibit 104); filing signed by Matthew Angel, Chief Executive Officer.

Why It Matters

• This 8-K provides investors with the company’s latest quarterly results and business highlights; the attached press release is the primary source for revenue, earnings (loss), cash position, guidance or clinical updates.
• Investors should read the press release and monitor the upcoming quarterly report (Form 10-Q) for the full financial statements and more detailed disclosures to assess Tempest’s recent performance and outlook.